Anti-Brd4 antibody [EPR5150(2)],Abcam,AB128874
Anti-Brd4 antibody [EPR5150(2)] (ab128874) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P and WB. Anti-Brd4 antibody [EPR5150(2)] (ab128874) was first used in a scientific publication in 2014 and has been cited over 163 times in peer reviewed journals. It's performance in Western Blot in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Brd4 antibody [EPR5150(2)] (ab128874) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-Brd4 antibody [EPR5150(2)] (ab128874) has been confirmed by Western Blot testing in Brd4 knockout Hap1 cells. Anti-Brd4 antibody [EPR5150(2)] (ab128874) has 17 independent reviews from customers. Anti-Brd4 antibody [EPR5150(2)] (ab128874) specifically detects Brd4 (UniProt ID: O60885; Molecular weight: 153kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR5150(2) - ab182446 . Antibody clone EPR5150(2) is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, HRP, Alexa Fluor ® 594 ( ab197606 , ab197608 , ab197609 , ab207057 ). Top cited antibody for this target with >200 citations. A highly specific BRD4 antibody, essential for studying bromodomain-containing protein 4, epigenetic regulation and chromatin remodeling. This antibody is crucial in cancer research, particularly in understanding BRD4's role in transcription regulation, chemoresistance and tumor progression and is widely used in studies of BRD4 inhibitors and BET proteins. Research has shown that BRD4 (and BET family proteins) may be promising therapeutic targets for various Myc-driven cancers, such as Burkitt's lymphoma and certain acute myeloid leukaemia's and is studied is a potential therapeutic target. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Shipping conditions update: ambient shipping This product will be delivered at ambient temperature instead of chilled – this is by design. Extensive stability testing confirmed that our products are suitable for shipment under ambient conditions and maintain expected quality. Why the change? It’s part of our commitment to more sustainable packaging solutions, with ambient deliveries using eco-friendly materials such as recyclable cardboard instead of polystyrene. What you need to know Ambient shipments come clearly marked on the delivery note. No ice will be included in ambient shipments, but mixed orders (ambient and cold-chain items) will still arrive with ice packs to protect temperature-sensitive products. Warranty coverage remains fully valid, aligned with our validated shipping method. Please store the product as per the datasheet instructions upon receipt. Find out more - https://www.abcam.com/en-us/support/shipping-storage-support/ambient-shipping
Host
Rabbit
Reactivity
Mouse, Human
Application
Flow Cyt (Intra), WB, ICC/IF, IHC-P
Platform ID
BAB982007934
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation (PubMed : 20871596, PubMed : 23086925, PubMed : 23317504, PubMed : 29176719, PubMed : 29379197). Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure (PubMed : 22334664, PubMed : 23317504, PubMed : 23589332). During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters (PubMed : 16109376, PubMed : 16109377, PubMed : 19596240, PubMed : 23589332, PubMed : 24360279). Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6 (PubMed : 16109376, PubMed : 16109377, PubMed : 19596240, PubMed : 23589332, PubMed : 24360279). BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II (PubMed : 16109376, PubMed : 16109377, PubMed : 19596240, PubMed : 23589332, PubMed : 24360279). Regulates differentiation of naive CD4(+) T-cells into T-helper Th17 by promoting recruitment of P-TEFb to promoters (By similarity). Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II (PubMed : 23086925). According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo (PubMed : 22509028). In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B (PubMed : 19103749). Also acts as a regulator of p53/TP53-mediated transcription : following phosphorylation by CK2, recruited to p53/TP53 specific target promoters (PubMed : 23317504).. Isoform B. Acts as a chromatin insulator in the DNA damage response pathway. Inhibits DNA damage response signaling by recruiting the condensin-2 complex to acetylated histones, leading to chromatin structure remodeling, insulating the region from DNA damage response by limiting spreading of histone H2AX/H2A.x phosphorylation. See full target information BRD4
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.